The Essex-based firm, which reported revenues of £13.9 million over the past year, has created an additional 200m² of ISO 7 cleanroom space at its Southminster facility. This expansion will support a recently secured medical contract and provide additional capacity for future opportunities.
New Capacity for Growth
The extended cleanroom space can now accommodate four extra moulding machines and new assembly lines, all meeting stringent ISO 7 cleanroom standards. It represents the next stage in a strategic investment programme that is approaching £4 million, aimed at increasing contract manufacturing sales by 20%.
Rory O’Keeffe, Commercial Director at Europlaz, commented:
“This is a timely and important development that allows us to scale with increasing customer demand. It also positions us well to take advantage of more European and US clients looking to reshore production from the Far East.”
New Contracts Already Underway
Europlaz has already installed two new injection moulding machines, with initial production runs supporting a contract with med tech specialist Olympus.
This immediate uptake underscores the market appetite for high-quality, UK-based contract manufacturing services, particularly in the healthcare sector.
Supporting Innovation in Medical Devices
Operating from its ISO13485-certified, state-of-the-art production facility on The Maltings Industrial Estate, near Chelmsford, Europlaz offers injection moulding, assembly, product validation, and modern ISO Class 7 cleanrooms for the manufacture of Class I, II, and III medical devices.
Recent highlights include contract manufacturing for innovations such as a home dialysis machine, a breath-operated inhaler, and a bio-artificial liver.
Boosting Patient Outcomes with Olympus
Europlaz’s latest success involves producing the ENDOCUFF VISION™ device for Olympus — a breakthrough colonoscopy accessory designed to increase adenoma detection rates by up to 11%.
For every 1,000 patients screened, studies estimate up to 110 additional patients with adenomas could be identified using this technology, enhancing patient care and outcomes.
The production process includes two-stage injection moulding, featuring an initial shot followed by overmoulding, with four different variants manufactured for UK, European, and international markets.
